{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:11:57Z","timestamp":1790230317320,"version":"4.1.0"},"reference-count":19,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Cervical cancer affects 12\u2009000 women in the United States annually. However, despite its prevalence, there remains no good methodology to detect its recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To identify the role of cervicovaginal high-risk human papilloma virus (hr-HPV) testing in predicting cervical cancer recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This is a retrospective study of patients who underwent hr-HPV testing as part of their routine surveillance for cervical cancer. Standard statistical analyses, including \u03c72 test and multivariable logistic regression, were performed with IBM SPSS 19.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 133 patients were identified, of whom 107 (80%) had squamous cell carcinoma. Ninety patients (68%) had bulky disease and were treated primarily with chemoradiation and brachytherapy. Of patients whose disease recurred, 5 patients (42%) had tested positive for hr-HPV during their surveillance period, compared to 13 patients (11%) for whom disease did not recur (relative risk: 3.88, P = .002). On multivariate logistic regression, hr-HPV status remained significantly predictive of disease recurrence (odds ratio: 12.3, P = .02, 95% confidence interval: 1.5\u201399.6). Using 2 \u00d7 2 table analysis, we found that while cervicovaginal cytology has limited specificity (5.7%) in predicting recurrence, the combination of cytology with hr-HPV testing increases the specificity of testing to 89.3%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Persistence of hr-HPV is a risk factor for disease recurrence. High-risk\u2013HPV testing is not routinely used during surveillance for cervical cancer, but this study suggests that large, prospective trials investigating the role of hr-HPV testing in cervical cancer surveillance are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2014-0534-oa","type":"journal-article","created":{"date-parts":[[2015,10,30]],"date-time":"2015-10-30T16:39:01Z","timestamp":1446223141000},"page":"1437-1440","source":"Crossref","is-referenced-by-count":15,"title":["The Role of High-Risk Human Papilloma Virus Testing in the Surveillance of Cervical Cancer After Treatment"],"prefix":"10.5858","volume":"139","author":[{"given":"Miao Crystal","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Marshall","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil","family":"Beriwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Comerci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paniti","family":"Sukumvanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander B.","family":"Olawaiye","sequence":"additional","affiliation":[{"name":"From the Departments of Gynecology Oncology (Drs Yu, Lin, Comerci, Edwards, Sukumvanich, Kelley, and Olawaiye), Pathology (Dr Austin), and Radiation Oncology (Dr Beriwal), Magee-Women's Hospital, Pittsburgh, Pennsylvania; and the Department of Gynecology Oncology, University of Washington, Seattle (Dr Beck)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","reference":[{"issue":"1","key":"2020081220274845700_i1543-2165-139-11-1437-b01","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papilloma virus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Wallboomers","year":"1999","journal-title":"J Pathol"},{"issue":"2","key":"2020081220274845700_i1543-2165-139-11-1437-b02","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2020081220274845700_i1543-2165-139-11-1437-b03","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"suppl 1","key":"2020081220274845700_i1543-2165-139-11-1437-b04","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S0020-7292(06)60030-1","article-title":"Carcinoma of the cervix uteri: FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer","volume":"95","author":"Quinn","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"issue":"3","key":"2020081220274845700_i1543-2165-139-11-1437-b05","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ygyno.2009.06.001","article-title":"Follow-up for women after treatment for cervical cancer: a systematic review","volume":"114","author":"Elit","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"6","key":"2020081220274845700_i1543-2165-139-11-1437-b06","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ajog.2011.03.008","article-title":"Post treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologist Recommendations","volume":"204","author":"Salani","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"11","key":"2020081220274845700_i1543-2165-139-11-1437-b07","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"De Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"2020081220274845700_i1543-2165-139-11-1437-b08","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1006\/gyno.1994.1058","article-title":"Human papillomavirus DNA in locally recurrent cervical cancer","volume":"52","author":"Ikenberg","year":"1994","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2020081220274845700_i1543-2165-139-11-1437-b09","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0090-8258(91)90270-F","article-title":"Identification of human papillomavirus 16 in primary and recurrent cervical cancer following radiation therapy","volume":"41","author":"Holloway","year":"1991","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2020081220274845700_i1543-2165-139-11-1437-b10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/IGC.0b013e3181c3a6b6","article-title":"High risk HPV genotyping in the follow-up of women treated conservatively for microinvasive cervical cancer","volume":"20","author":"Cairns","year":"2010","journal-title":"Int J Gynecol Cancer"},{"issue":"suppl 5","key":"2020081220274845700_i1543-2165-139-11-1437-b11","first-page":"S38","article-title":"Human papillomavirus infection following radiation therapy or concurrent chemoradiation for invasive cervical cancer","volume":"95","author":"Intharaburan","year":"2012","journal-title":"J Med Assoc Thai"},{"key":"2020081220274845700_i1543-2165-139-11-1437-b12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/jmv.2015","article-title":"Detection of high risk HPV types by the hybrid capture 2 test","volume":"65","author":"Terry","year":"2001","journal-title":"J Med Virol"},{"issue":"4","key":"2020081220274845700_i1543-2165-139-11-1437-b13","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1309\/AJCPTGD94EVRSJCG","article-title":"American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer","volume":"137","author":"Saslow","year":"2012","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"2020081220274845700_i1543-2165-139-11-1437-b14","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/IGC.0b013e3181a832a2","article-title":"Comparison of the hybrid capture ii assay with the human papilloma DNA chip for the detection of high-grade cervical lesions","volume":"19","author":"Kang","year":"2009","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"2020081220274845700_i1543-2165-139-11-1437-b15","first-page":"94","article-title":"The Abbott Real Time High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test","volume":"18","author":"Poljak","year":"2009","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"issue":"1","key":"2020081220274845700_i1543-2165-139-11-1437-b16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1158\/1055-9965.EPI-12-0953-T","article-title":"Prospective study of HPV 16 viral load and risk of in-situ and invasive squamous cervical cancer","volume":"22","author":"Sundstrom","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"2020081220274845700_i1543-2165-139-11-1437-b17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jcv.2005.07.011","article-title":"Association of high-risk HPV types and viral load with cervical cancer in China","volume":"35","author":"Wu","year":"2006","journal-title":"J Clin Virol"},{"issue":"5 suppl 1","key":"2020081220274845700_i1543-2165-139-11-1437-b18","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1097\/LGT.0b013e31828543c5","article-title":"Five year risk of recurrence after treatment of CIN 2, 3 or AIS: performance of HPV and Pap cotesting in post treatment management","volume":"17","author":"Katki","year":"2013","journal-title":"J Low Genit Tract Dis"},{"issue":"4","key":"2020081220274845700_i1543-2165-139-11-1437-b19","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/LGT.0000000000000012","article-title":"Post treatment assessment of women at risk of developing high grade cervical disease: proposal for new guidelines based on data from the Netherlands","volume":"18","author":"Uijterwaal","year":"2014","journal-title":"J Low Genit Tract Dis"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/139\/11\/1437\/1613671\/arpa_2014-0534-oa.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/139\/11\/1437\/1613671\/arpa_2014-0534-oa.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:35:38Z","timestamp":1764790538000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/139\/11\/article-p1437.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,1]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2014-0534-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11,1]]}}}